This podcast episode provides a summary of the final day of the DGN Congress 2025. The hosts, Prof. Mathias Mäurer and Prof. Tobias Ruck, along with their guest Prof. Mathias Buttmann, discuss key developments in neurology. The main focus is on Multiple Sclerosis (MS), covering the increasing importance of focal inflammation in Progression Independent of Relapse Activity (PIRA), the clinical application of biomarkers like Neurofilament light chain (NFL), and the challenges of interpreting these markers without standardized Z-scores. The discussion then turns to the role of Artificial Intelligence (AI) in neurology, both for patient stratification and for administrative tasks like medical report generation, highlighting practical tools and implementation hurdles. Finally, the hosts review recent press release data on the BTK inhibitor Fenebrutinib, noting its promising results in both relapsing MS and PPMS, which supports the therapeutic potential of the drug class. A brief mention is made of the significant presence of epilepsy-related topics at the congress.
Key Discussions from the DGN Congress 2025 Recap
1:26 MS Progression (PIRA): A central theme was that focal inflammation plays a more significant role in Progression Independent of Relapse Activity (PIRA) than previously thought. This shifts the focus back towards classic inflammatory markers, even when assessing progression.
2:24 Biomarkers (NFL): For Neurofilament light chain (NFL) measurement, it is critical to use Z-scores, which account for covariates like age and BMI, rather than absolute values. Practical implementation is hampered by the lack of standardized Z-score reporting from most labs and cost issues.
4:15 MRI as a Predictive Tool: Data from a long-term Barcelona cohort reaffirmed that classic MRI markers, particularly T2 lesion load, remain the strongest predictors of long-term disability progression over periods up to 20 years.
6:54 AI for Patient Stratification: A presentation on an AI model that categorizes MS patients into different Verlaufstypen (course types) was highlighted. A key finding is that patients seemingly must pass through a specific "active phase" to develop a severe disease course, suggesting there is no going back from that stage.
7:50 Practical AI Applications: The discussion covered AI tools for clinical administration, such as automated medical report generation (Argo) and advanced speech recognition (Offro) developed in Hamburg. These tools promise significant time savings but face adoption barriers due to high initial costs for hospitals.
12:16 BTK Inhibitor Updates: A press release on Fenebrutinib showed superiority over Teriflunomide in controlling focal inflammation in relapsing MS. In Primary Progressive MS (PPMS), it demonstrated non-inferiority to Ocrelizumab, with data suggesting potential numerical superiority in preventing disability progression after 24 weeks. This reinforces confidence in the BTKi therapeutic approach.
14:43 Other Congress Highlights: The hosts noted that Epilepsy was a major topic at the congress, with many educational sessions, including one on epilepsy during pregnancy, reflecting a need for neurologists to maintain broad expertise outside their subspecialties.